May 22 (Reuters) – A European Medicines Agency committee said on Friday it has adopted a positive opinion of AstraZeneca’s experimental breast cancer drug, camizestrant.
The positive opinion comes weeks after a U.S. Food and Drug Administration advisory panel voted against the treatment, raising concerns about the design of a key late-stage trial rather than the treatment’s safety or effectiveness.
AstraZeneca expects up to 20 new medicine launches by 2030 to hit its $80 billion revenue target, including potential U.S. approval this year for camizestrant, which the firm expects will generate more than $5 billion in peak annual sales.
(Reporting by Ankita Bora in Bengaluru; Editing by Tasim Zahid and Devika Syamnath)
Comments